Temsirolimus (also known as CCI-779) is a recently developed mTOR inhibitor, with improved aqueous solubility and more favorable pharmaceutical properties compared with the parent compound rapamycin.
Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.

1. Shuuin T, Karashima H.[Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.

2. Mounier N, Vignot S, Spano JP.[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].Bull Cancer. 2006 Nov;93(11):1139-43.